Israeli Survey On OTC Medicines

15 January 1996

A survey by the Israeli OTC drug industry association, Telem, has found that 25% of people thought Moxypen (amoxicillin) was an over-the counter drug. Acamol (paracetamol) is the best-known medication, followed by Optalgin (pain reliever), Coldex (cold remedy) and centrum (vitamins), it found.

Two-thirds of those polled read the patient package insert, with women more likely to do so than men, and people aged 18-29 and the elderly less likely to do so. Telem chairman Ze'ev Baber said demand for OTCs is rising due to growing longevity and income, more private pharmacies and chain stores, and more education. About 12% of drugs in Israel are sold without prescription, mainly in private pharmacies, in a market worth $53 million a year. the average Israeli spends $11 a year on OTC drugs (compared with $48 in the USA), mostly on vitamins, analgesics and skin preparations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight